Table 1.
Summary of studies examining neoadjuvant chemotherapy in advanced endometrial cancer.
| Reference | Study Design | Years Analyzed | Stages Included | NACT Regimen* | NACT | Histologies NACT | PDS | Histologies PDS |
|---|---|---|---|---|---|---|---|---|
| n | n (%) | n | n (%) | |||||
| Bogani et al., 2019 | Retrospective cohort, propensity-matched | 2005–2016 | IVb | 3-6 cycles paclitaxel/carboplatin or cisplatin ± doxorubicin | 15 | 15 (100) serous | 15 | 15 (100) serous |
| de Lange et al., 2019 | Retrospective case-series | 2005–2014 | III, IV | 1-6 cycles paclitaxel/carboplatin | 102 | 44 (43) endometrioid 44 (43) serous 4 (4) clear cell 10 (10) other or mixed |
– | – |
| Eto et al., 2013 | Retrospective cohort | 1996–2005 | IVb | 63% taxane + platinum 30% doxorubicin + platinum ± other 7% other Cycle numbers not reported |
125 | 68 (54) endometrioid 57 (46) non-endometrioid |
279 | 163 (58) endometrioid 116 (42) non-endometrioid |
| Holman et al., 2017 | Retrospective cohort | 1993–2012 | III, IV | NACT details not reported | 27 | 19 (70) serous 8 (30) mixed |
233 | 79 (34) serous 154 (66) mixed |
| Khouri et al., 2019 | Retrospective case-series | 2002–2016 | NR | 85% paclitaxel/carboplatin 10% carboplatin only 5% paclitaxel only Cycle numbers not reported |
39 | 11 (28) endometrioid 17 (44) serous 3 (8) clear cell 4 (10) carcinosarcoma 1 (3) neuroendocrine 3 (8) mixed |
– | – |
| Rajkumar et al., 2019 | Retrospective cohort | 2010–2016 | IIIC, IV | 3-6 cycles taxol/carboplatin or cisplatin/doxorubicin | 17 | NR | 28 | NR |
| Tobias et al., 2020 | Retrospective cohort | 2010–2015 | IV | NR | 952 | 223 (23) endometrioid 249 (26) serous 34 (4) clear cell 115 (12) carcinosarcoma 90 (9) sarcoma 188 (20) EM NOS 53 (6) other |
3938 | 1114 (28) endometrioid 828 (21) serous 117 (3) clear cell 612 (16) carcinosarcoma 554 (14) sarcoma 614 (16) EM NOS 99 (3) Other |
| Vandenput et al., 2009 | Prospective cohort | 1999–2007 | IV | 3-4 cycles paclitaxel/carboplatin or doxorubicin/cisplatin | 30 | 2 (7) endometrioid 27 (90) serous 1 (3) clear cell |
– | – |
| Wilkinson-Ryan et al., 2015 | Retrospective cohort | 2000–2013 | IV | 3-8 cycles taxane/platinum | 10 | 10 (100) serous or mixed histology with >50% serous component | 34 | 34 (100) serous or mixed histology with >50% serous component |
NACT = neoadjuvant chemotherapy, IDS = interval debulking surgery, PD = primary debulking surgery.
EM NOS = endometrioid not otherwise specified.
NR = not reported.
*
Summaries of the most common NACT regimens are listed, as studies reported highly variable NACT regimens.